MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021
Cemiplimab plus ipilimumab for advanced NSCLC
Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )
7 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )
1 Apr 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )
29 Mar 2021
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 inserti...
Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passa...
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )
29 Mar 2021
Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC i...
Prof Andrea Filippi - University of Pavia, Pavia, Italy
Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy ( Prof Andrea Filippi - University of Pavia, Pavia, Italy )
26 Mar 2021
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES)
Dr Giuseppe Giaccone, Dr Marina Garassino
Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES) ( Dr Giuseppe Giaccone, Dr Marina Garassino )
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT)
Dr Giuseppe Giaccone, Dr Marina Garassino
Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT) ( Dr Giuseppe Giaccone, Dr Marina Garassino )
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)
Dr Giuseppe Giaccone, Dr Marina Garassino
Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE) ( Dr Giuseppe Giaccone, Dr Marina Garassino )
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR)
Dr Giuseppe Giaccone, Dr Marina Garassino
Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR) ( Dr Giuseppe Giaccone, Dr Marina Garassino )
2 Mar 2021
Reducing the risk of contracting COVID-19 in patients with NSCLC (IT)
Dr Giuseppe Giaccone, Dr Neal Navani, Professor Eric Lim
Reducing the risk of contracting COVID-19 in patients with NSCLC (IT) ( Dr Giuseppe Giaccone, Dr Neal Navani, Professor Eric Lim )
2 Mar 2021